IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions

Area of Science:

• Gastroenterology
• Microbiome Research
• Integrative Medicine

Background:

• Irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO) present overlapping symptoms like abdominal pain and bloating.
• Both conditions are associated with gut dysbiosis and gut-brain axis dysfunction.
• SIBO involves excessive small intestinal bacteria, potentially mimicking or exacerbating IBS.

Purpose of the Study:

• To review the pathophysiology and microbiota interactions in IBS and SIBO.
• To evaluate non-pharmacological interventions for IBS and SIBO.
• To advocate for non-antibiotic strategies to mitigate risks of antibiotic resistance and microbiome disruption.

Main Methods:

• Literature review synthesizing current evidence on IBS/SIBO pathophysiology.
• Evaluation of non-pharmacological interventions including dietary approaches, probiotics/prebiotics, herbal therapies, and mind-body treatments.
• Analysis of microbiota interactions and their influence on gut function.

Main Results:

• Gut microbes and metabolites significantly impact motility, immune function, barrier integrity, and gas production.
• Specific microbial overgrowths (methanogens, hydrogen/hydrogen sulfide producers) correlate with distinct symptom presentations.
• Non-antibiotic strategies offer a viable alternative for managing IBS/SIBO symptoms.

Conclusions:

• An integrative approach combining dietary changes, probiotics, prebiotics, and mind-body therapies can effectively manage IBS and SIBO.
• Prioritizing non-antibiotic treatments is crucial for reducing risks associated with recurrent antibiotic use.
• Focusing on symptom control and quality of life supports patients with IBS and SIBO.